Don't overlook any of the groundbreaking basic science research presented at The TLMdX. New this year, an expert will briefly review of all the basic science abstracts presented at the meeting in one condensed session.
Digest a debrief of the newest data on the treatment of viral hepatitis presented at TLMdX in 2020. This unique session synthesizes the results from this yearâs abstracts, condensed and discussed by an expert in the field.
Donât overlook any of the research presented at TLMdX that directly impacts patients. New this year, an patient advocate will briefly review of all the abstracts presented at the meeting that significantly impacted the role of the patient in one condensed session.
Review key highlights from all the exciting clinical research presented at TLMdX this year at this condensed round-up session, which is designed to complement the highly regarded Basic, Hepatitis and Clinical Hepatology Debriefs.
Haesuk Park, Hyun Jin Song, Xinyi Jiang, Linda Henry, Robert L. Cook, David R. Nelson – 17 November 2020 – Medicaid prior authorization (PA) policies for treatment of hepatitis C virus (HCV) with direct‐acting antiviral (DAA) therapy are changing. We aimed to evaluate effects of changes in PA requirements on treatment uptake and to determine the factors associated with DAA treatment among Florida Medicaid beneficiaries with HCV. This is a retrospective cohort analysis of Florida’s Medicaid administrative claims and electronic medical records (2013‐2018).
Edoardo Poli, Celine Verstuyft, Catherine Guettier, Jean‐Charles Duclos Vallée – 17 November 2020
Zachary M. Saleh, Patricia P. Bloom, Katie Grzyb, Elliot B. Tapper – 17 November 2020 – The complexity of cirrhosis requires patients and their caregivers to be well educated to improve outcomes. Data are lacking regarding how to best educate patients and their caregivers in the setting of cirrhosis. Our aim is to understand (both through existing literature and by asking patients and their caregivers) how patients learn about their disease, barriers in their education and disease management, and self‐management strategies.
The focus of the 2020 AASLD/ASGE Postgraduate Course is the role of endoscopic interventions, and how they may be used to enhance medical and surgical management of patients with hepatobiliary diseases. In an engaging debate format, experts will discuss challenging and sometimes controversial patient cases and topics. Participants are encouraged to interact with faculty during the debates and panel discussions.
Biologic drugs are commonly prescribed for autoimmune conditions and malignancies. How do we manage biologicsâ effect on the liver? Acute liver failure has been reported in some patients on TNF-alpha inhibitors. Checkpoint inhibitors that modulate T-cell immune reactivity in cancer are frequently associated with liver injury. This session explores monitoring of liver tests, therapy cessation, corticosteroids and other hot topics.
Review a condensed summary of the clinical research highlights from TLMdX in 2020. This popular debriefing session summarizes all the important findings in clinical hepatology that were presented this year.